The Native Antigen Company Launches SARS-CoV-2 Assay Kit
The Native Antigen Company, part of LGC Clinical Diagnostics and one of the world’s leading suppliers of reagents that enables research into diagnostics and vaccines for emerging and endemic infectious diseases, today announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit. The kit can be used to identify and qualitatively assess the ability of antibodies to neutralize SARS-CoV-2-receptor binding, to support research into variants and their effects on natural and vaccine-induced patient immunity. The easy-to-use kit contains all the key reagents required to measure SARS-...
Source: news-medical.net